X4 Pharmaceuticals, Inc. XFOR
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -20.75%
- 1 year
- -22.49%
- Market cap
- 314.30M
- Revenue (ttm)
- 563.00K
- Profit margin
- 3131.79%
- EPS (ttm)
- 0.02
- Shares out
- 170.55M
- P/E ratio
- 158.50
- Forward P/E
- -1.23
- YTD return
- -20.75%
- 1-year return
- -22.49%
- Volume
- 630.98K
- Avg volume
- 861.16K
- Open
- 3.37
- Previous close
- 3.35
- Day's range
- 3.14 – 3.42
- 52-week range
- 2.43 – 4.83
- Beta
- 0.39
- Analysts
- Strong Buy
- Price target
- 3.05 (-3.8%)
- Earnings date
- Aug 8, 2024
1Y -0.80 (-20.15%)
Key statistics
- Enterprise value
- 9.24M
- PEG ratio
- 0.00
- Price / sales
- 174.82
- Price / book
- 1.89
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -71.71M
- Total cash
- 168.75M
- Total debt
- 78.23M
- Return on equity
- 21.77%
- Short % of float
- 6.84%
- 50-day average
- 0.50158
- 200-day average
- 0.79766
Analyst view
Consensus: strong buy
- Target (low)
- 1.50
- Target (mean)
- 3.05
- Target (high)
- 4.00
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.1575.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.17 | -0.18 | -0.01 | -5.88% |
| Aug 8, 2024 | Jun 1, 2024 | -0.05 | -0.07 | -0.02 | -40.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.05 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.17 | -0.26 | -0.09 | -52.94% |
| May 7, 2024 | Mar 1, 2024 | -0.17 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.15 | -0.10 | +0.05 | +33.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 14, 2024 | Stifel | main | Buy | Buy |
| Jun 28, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 31, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Apr 30, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Mar 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- x4pharma.com
News
X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026 
4 Biotech Stocks Seeing Unusual Options Volume Today 
X4 Pharmaceuticals, Inc. (XFOR) Analyst/Investor Day Transcript 
X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day 
X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia 
Head to Head Review: Entrada Therapeutics (NASDAQ:TRDA) versus X4 Pharmaceuticals (NASDAQ:XFOR) 
X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders 
X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures 
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock Rated “Moderate Buy” by Sell-Side Brokerages 
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Your note
Sign in to keep a note on XFOR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALISKI WILLIAM E | Director | Stock Award(Grant) | Jun 9, 2024 | 96,667 |
| BALDRY MARK | Officer | Sale | Oct 6, 2024 | 48,509 |
| DE CRAECKER FRANCOISE | Director | Stock Award(Grant) | Jun 9, 2024 | 96,667 |
| DIBIASE MARY | Chief Operating Officer | Sale | Oct 6, 2024 | 452,060 |
| MCGIRR DAVID W J | Director | Stock Award(Grant) | Jun 9, 2024 | 96,667 |
| MOSTAFA ADAM S. | Chief Financial Officer | Sale | Oct 6, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 9.92% | 16,915,784 | 9.76M | Sep 29, 2024 |
| NEA Management Company, LLC | 8.79% | 14,986,793 | 8.65M | Sep 29, 2024 |
| Blackrock Inc. | 6.57% | 11,210,671 | 6.47M | Sep 29, 2024 |
| Vanguard Group Inc | 4.95% | 8,440,730 | 4.87M | Sep 29, 2024 |
| Orbimed Advisors LLC. | 4.18% | 7,133,515 | 4.12M | Sep 29, 2024 |
| Kingdon Capital Management LLC | 2.72% | 4,638,683 | 2.68M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.95% | 5,034,386 | 2.91M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.46% | 4,195,788 | 2.42M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.14% | 1,935,936 | 1.12M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.02% | 1,739,242 | 1.00M | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.96% | 1,639,835 | 946.35K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.43% | 731,215 | 421.98K | Oct 30, 2024 |